Corpus 1,273 assessed · 1,174 scored · 643 reproduced ≥75 · 169 flagged ·∅ 74.1/100

Publications 2 Datasets 392.5k Experiments 4.7k

Explore

Filters: Cell Rep Med ✕ 2024 ✕ clear all

2 matching publication(s)

Publication	Journal	Year	Score	Verdict
Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant NSCLC: Phase 2 trial interim results (NEOTIDE/CTONG2104). PMID 38897205	Cell Rep Med	2024	72	L1 72/100
Single-cell multiomics profiling reveals heterogeneous transcriptional programs and microenvironment in DSRCTs. PMID 38781959	Cell Rep Med	2024	76	L1 76/100

Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant NSCLC: Phase 2 trial interim results (NEOTIDE/CTONG2104).

PMID 38897205 · Cell Rep Med · 2024

L1 72/100

Single-cell multiomics profiling reveals heterogeneous transcriptional programs and microenvironment in DSRCTs.

PMID 38781959 · Cell Rep Med · 2024

L1 76/100